Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | -3.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.46 | N/A | -3.14% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial landscape. They did not provide future guidance, indicating uncertainty in upcoming performance.
Management did not provide specific guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
Nektar Therapeutics reported a loss that was slightly worse than expected, leading to a 1.12% drop in stock price. The lack of revenue figures and forward guidance adds to investor uncertainty. The company's challenges in achieving profitability may weigh on future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FIRSTENERGY CORP
Feb 25, 2013